Cost Management Insights: SG&A Expenses for Ligand Pharmaceuticals Incorporated and Soleno Therapeutics, Inc.

Explore SG&A trends in Ligand and Soleno's financial strategies.

__timestampLigand Pharmaceuticals IncorporatedSoleno Therapeutics, Inc.
Wednesday, January 1, 2014225700002917513
Thursday, January 1, 2015243780007878291
Friday, January 1, 2016266210008366794
Sunday, January 1, 2017286530006610381
Monday, January 1, 2018377340006556000
Tuesday, January 1, 2019418840006930000
Wednesday, January 1, 2020644350008758000
Friday, January 1, 20215748300010806000
Saturday, January 1, 2022700620009844000
Sunday, January 1, 20235279000013481000
Loading chart...

Unleashing insights

Cost Management Insights: SG&A Expenses

A Decade of Financial Strategy

In the ever-evolving pharmaceutical landscape, effective cost management is crucial. Over the past decade, Ligand Pharmaceuticals Incorporated and Soleno Therapeutics, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Ligand Pharmaceuticals has seen a significant increase, with expenses peaking in 2022, marking a 210% rise from 2014. This growth reflects their aggressive expansion and investment in operational capabilities. In contrast, Soleno Therapeutics has maintained a more conservative approach, with a steady increase of approximately 360% over the same period, indicating a focus on sustainable growth.

Strategic Implications

These trends highlight the strategic priorities of each company. Ligand's higher SG&A expenses suggest a focus on scaling operations, while Soleno's steady increase points to a balanced approach, ensuring financial stability while pursuing growth opportunities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025